San Diego, CA -- (SBWIRE) -- 04/16/2015 -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) http://www.innovuspharma.com/ (OTCQB:INNV) a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases announced today that its partner Sothema Laboratories, ("Sothema") received marketing authorization for Zestra® in the United Arab Emirates (the "UAE").

"We are very happy with the progress being made by our partner Sothema on the commercialization of Zestra® in its licensed territories. Although this partnership was signed in late 2014, Sothema has been very aggressive in its approval and launch timelines as they already received approvals in two countries (Morocco and the UAE) and launched in Morocco and expected to launch in the UAE very shortly. We look forward to a successful launch in the UAE and the rest of the countries in the Sothema territory," said Dr. Bassam Damaj, President & Chief Executive Officer of Innovus Pharma. Sothema initiated the filing for Zestra® in most of its licensed territories so we expect Zestra® to be available in many countries in 2015 continued Dr. Damaj.

The Company is scaling up its manufacturing by four times to accommodate the current product orders from its partners.

On September 28, 2014, Innovus Pharma granted to Sothema an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder ("FSI/AD") as approved by Health Canada, Zestra®, and its high viscosity water-based lubricant Zestra Glide® in the North African countries, the Gulf Countries Middle East (excluding Lebanon and Israel) and in certain countries in West Africa. Under the agreement as disclosed at that time, Innovus received an upfront payment and is eligible to receive up to approximately $171.25 million U.S. dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory plus a pre-negotiated transfer price per unit.

About Zestra® and FSI/AD
Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Zestra® is currently available in the United States, Canada and Morocco.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and FlutiCare™ OTC for Allergic Rhinitis.

For more information, go to http://www.innovuspharma.com/, http://www.zestra.com/ ; http://www.ejectdelay.com/ ; UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (SBWIRE) -- 02/05/2015 -- - Transformative acquisition establishes Innovus's position as a leading respiratory OTC Pharmaceutical Company

- Adds significant potential revenue and net sales upon the approval of the U.S. Abbreviated New Drug Application ("ANDA") for FlutiCare(TM) compared to recent Company guidance

- The Company expects potential significant growth in net sales, EBITDA, non-GAAP earnings and cash flow following ANDA approval

- Strong fundamental returns - potential return on the Company's invested capital estimated to exceed cost of capital by 2016-2017

- Directly leverages Innovus's existing infrastructure and expertise in the OTC retail and online space

- Fluticasone propionate nasal spray ("FPNS") is the #1 most prescribed nasal steroid in the U.S. since 2007, with more than 150 million units sold

- FlutiCare(TM) is a nasal spray in the form that has been the #1 prescribed nasal spray to patients in the US for more than five consecutive years

- More than 40 million units of FlutiCare(TM) nasal spray product form have been sold in the U.S. in 2014

- Innovus plans to expand internationally with FlutiCare(TM) and launch in additional countries subject to regulatory approval

- Following the merger, Novalere will become a wholly-owned subsidiary of Innovus Pharma

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it acquired the worldwide rights to the Fluticare(TM) brand (Fluticasone propionate nasal spray) from Novalere FP., Inc. ("Novalere") through a merger.

Innovus Pharma expects that the ANDA may be approved by the end of 2015 or in the first half of 2016 by the U.S. Food and Drug Administration ("FDA"). An ANDA is an Abbreviated New Drug Application reviewed and approved by the Office of Generic Drugs of the FDA for a generic version of a currently approved drug.

"This transaction is transformative for Innovus. The nasal steroid market in the United States is undergoing a revolution with the expected launch of fluticasone propionate nasal spray in the U.S., transitioning this market to an Over-the-Counter ("OTC") market," said Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. "We expect to play a significant role in this market and hopefully in other markets throughout the world by proposing to consumers an alternative product using the product form they have been used to as a prescription medicine for years. Access to the same product form for consumers may support better compliance and better outcome for consumers; many of them use the nasal spray on a continuous basis because they have a chronic condition."

"There is significant synergy between the potential of FlutiCare(TM) and the growing infrastructure Innovus Pharma is building both domestically and internationally. We expect that our capabilities and infrastructure together with the investor support will take Innovus to the next level as a growing profitable OTC company," he continued.

About FlutiCare(TM)
Fluticasone propionate 50 mcg spray, is the No. 1 prescribed allergy treatment ingredient[1] for temporary relief of the symptoms of hay fever or upper respiratory allergies.[2]
Roughly 50 million people in the United States suffer from nasal allergies[3], and allergies take a toll on sufferers:

- Nasal allergies can lead to fatigue, sleep disturbances, learning and attention problems and impaired function at work and/or school.[4]
- 70 percent of sufferers treat their symptoms with prescription or OTC treatments[5]; however, 50 percent of them report they are not completely satisfied with their current method of treatment.[6]
Fluticasone propionate has helped more allergy sufferers than any other nasal spray and has a well-established safety profile with 30 million accumulated patient years since it was first approved as a prescription medicine in 1994.[7]

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health and Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality.

For more information, go to www.innovuspharma.com; www.zestra.com;www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; http://www.myandroferti.com.

About Novalere F.P., Inc.
Based in Boston, MA Novalere FP is a consumer healthcare company developing and commercializing differentiated non-prescription products.

References
[1] Sur D, et al. Treatment of Allergic Rhinitis. American Family Physician. Volume 81, Number 12, June 15, 2010.

[2] American College of Allergy, Asthma and Immunology: Allergy facts. Available at: http://www.acaai.org/allergist/news/Pages/Allergy_Facts.aspx. Accessed July 2014.

[3] American College of Allergy, Asthma and Immunology: Allergic diseases and cognitive impairment. Available at: http://www.acaai.org/allergist/allergies/Types/rhinitis/Pages/allergic-diseases-cognitive-impairment.aspx. Accessed July 2014.

[4] Academy of Allergy and Asthma in Primary Care: National impact of allergies. Available at: http://www.aaapc.us/wp-content/uploads/2013/01/National-Impact-of-Allergies.pdf. Accessed July 2014.

[5] Scadding G, Punekar Y. EAACI 2006, Abstract 742.

[6] New Survey Reveals Many Patients Want More from Their Allergy Medication. Asthma and Allergy Foundation of America. Available at: http://www.aafa.org/display.cfm?id=7&sub=92&cont=529. Accessed April 24, 2014.

[7] Data on file.

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval of the ANDA in the U.S. or to be compliant with the requirements of any relevant regulatory authority relating to Fluticare(TM), to successfully commercialize this product and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Lynnette Dillen, EVP and CFO
ir@innovuspharma.com
858.964-5123

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (SBWIRE) -- 01/28/2015 -- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and vitality, announced today that it entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Androferti®, a patented and clinically proven product to support male reproductive health and sperm quality, in the U.S. and Canada.

Androferti®, has been shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and enhance spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperm ("REM")).

Androferti® is the only product clinically proven to increase the sperm quality and enhance spermatozoa quality as compared to other products where the claims are based on an ingredient used in such products.

"Androferti® is a great addition to our growing pipeline in men's health products. With our already existing retail and online infrastructure, we currently believe that we should be able to launch the product in Q2-Q3 of this year following claim clearance from the U.S. Food and Drug Administration," said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma.

"According to reports by IBIS World August 2014, the fertility market is estimate to be around $2 billion with a 2.5% yearly increase. With only 682 In-Vitro Fertility clinics in the U.S. we should be able to reach all of these clinics within a relatively short period of time," continued Dr. Damaj.

We are excited to partner with Innovus Pharma on the commercialization of our product Androferti®," said Cesar Quintanilla, President & Chief Executive Officer of Q Pharma. "Androferti® is a best seller in multiple European countries due to its proven clinical efficacy and we look forward to a successful launch of the product in the U.S. and Canada.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+®, for the indication of penile sensitivity, (for sales outside the U.S. only), Zestra Glide® and Vesele® for promoting sexual and cognitive health.

For more information, go to http://www.innovuspharma.com/, http://www.zestra.com/;http://www.myvesele.com/; http://www.ejectdelay.com/ and http://www.sensumplus.com/#/home/

Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to Androferti, to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Lynnette Dillen, EVP and CFO
ir@innovuspharma.com
858-964-5123

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Innovus Eligible to Receive up to $13 Million in Sales Milestone Payments plus 50% Royalties on Sales of Vesele®

San Diego, CA -- (SBWIRE) -- 12/16/2014 -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCQB:INNV) announced today it has expanded its exclusive marketing and distribution agreement with Tramorgan Limited ("Tramorgan") ,and granted to Tramorgan additional rights to market and sell Innovus Pharma's oral dietary supplement to promote sexual and cognitive health, Vesele® in the United Kingdom ("UK"). Under the agreement, Innovus is eligible to receive up to $13 million dollars in sales milestone payments plus fifty percent (50%) royalties based on Tramorgan's sales of Vesele® in the UK.

The product will be available in a 120 capsule bottle and will be priced at $26.50 per bottle online and $32.00 in retail stores.

"This is an expansion of our agreement with Tramorgan and our first agreement in Europe for the distribution and sale of Vesele®. We are very pleased with our relationship with Tramorgan and the level of sales we are beginning to see from their efforts", said Dr. Bassam Damaj, Ph.D. President & CEO of Innovus Pharma.

"We continue to expand the markets for our products as we approach our goal to make all of our products available in at least 40 countries by the end of 2015," continued Dr. Damaj.

"Our ability to secure a distribution and sales agreement in a large European market for Vesele®, a product that we acquired recently, is a testimony to the strength and readiness of our international distribution channels and the robustness of our distribution infrastructure," added Dr. Damaj.

About Vesele®
Vesele® is a proprietary, novel oral dietary supplement to maximize nitric oxide's beneficial effects on sexual function and brain health. Vesele® contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine®.

The beneficial effects of Vesele® on sexual and cognitive functions were confirmed in a four month US clinical survey study involving 152 patients (69 men and 83 women). Results from the clinical survey have indicated (1) improvement of erectile hardness and maintenance in men and increased sexual intercourse frequency with their partners and (2) lubrication in women, when taken separately by each. Positive effects on brain health were translated by an increase in recall of words and names.

For more information visit http://www.myvesele.com/

About Tramorgan
Tramorgan is a UK-based company with many years of experience in assisting European and global pharmaceutical companies to expand and deliver their products to markets in Europe and other countries. Tramorgan specializes in niche products that require specialist knowledge and market expertise in obtaining sales through the UK NHS hospital market, as well as OTC and other medical channels. The Company provides advice to healthcare organizations, universities and other commercial operations, wishing to develop or spin out unique pharmaceutical product portfolios or innovations and commercialize them for competitive international markets.
For more information about Tramorgan, please contact Heather Crawford at hc@tramorgan.co.uk.com

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal, and EjectDelay™ for premature ejaculation, and has a total of five marketed products in this space, including Sensum® (for sales outside the U.S. only), Zestra Glide® and Vesele® for promoting sexual and cognitive health.

For more information, go to http://www.innovuspharma.com/; http://www.ejectdelay.com/; http://www.zestra.com/; http://www.sensumplus.com/; http://www.myvesele.com/

Innovus Pharma's Forward-Looking Safe Harbor Statements
Under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether Tramorgan will be able to successfully market and sell Vesele® in the United Kingdom. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Innovus Pharma Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930

UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (SBWIRE) -- 11/06/2014 -- Innovus Pharmaceuticals, Inc. (OTCQB:INNV), a provider for over the counter men's and women's health products, will release its third quarter 2014 financial results on Friday, November 14, 2014 when it expects to file its Form 10-Q for the 2014 third quarter.

The Company currently expects to meet its revenue guidance of $1.2-1.5 million for the year ending December 31, 2014, its first year of revenues.

"We are pleased with the revenue growth the Company is experiencing which is a direct result of the Company's execution of its international growth strategy to sign commercial partnerships for the expanded distribution of our products. Our current partners operate in 28 countries and will provide the Company a platform for continued growth. The Company projects its income to come from a balance of organic growth of both domestic and international sales through our commercial partners. Our pipeline remains robust and we anticipate adding additional products moving forward," said Dr. Bassam Damaj, the Company's President and CEO.

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging company in the over-the-counter male and female sexual dysfunction and vitality products. The Company generates revenues from its lead products Zestra(R) for female arousal, and EjectDelay(TM) for premature ejaculation, and has a total of five marketed products in this space including Sensum+(TM) (for sales outside the U.S. only), Zestra(R) Glide and Vesele(R).
For more information, go to http://www.innovuspharma.com/index.php.

INNOVUS PHARMA'S FORWARD-LOOKING SAFE HARBOR
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives including, but not limited to, achieving its fiscal year 2014 financial revenue goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Innovus Pharma Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930

SOURCE: Innovus Pharma

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm